Company Overview of Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc., a clinical-stage company, focuses on the development of catalytic biopharmaceutical products based on engineered human proteases. It focuses on drug discovery for hemostasis, hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation. The company develops FVIIa, an enzyme that initiates blood clotting; FIX, a recombinant human factor IX for treating acute bleeding episodes in hemophilia B patients; and FXa, a pro-coagulant and bypass agent to control bleeding during surgery and trauma for hemophilia inhibitor patients and general population. It develops drugs for ischemia reperfusion inj...
260 Littlefield Avenue
South San Francisco, CA 94080-7019
Founded in 2002
Key Executives for Catalyst Biosciences, Inc.
Chief Executive Officer and Director
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Catalyst Biosciences, Inc. Key Developments
Catalyst Biosciences, Inc., Targacept, Inc. - M&A Call
Mar 5 15
To discuss proposed merger between the two companies
Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM
May 31 14
Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Nassim Usman, Chief Executive Officer and Director.
Catalyst Biosciences, Inc. and Isu Abxis Form Strategic Collaboration
Oct 9 13
Catalyst Biosciences, Inc. and Isu Abxis announced the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of Phase 1 clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients. Under the terms of the collaboration, Isu Abxis will use its biologics manufacturing and development expertise to advance FIX-NG through preclinical and Phase 1 studies and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an upfront licensing fee and milestone payments through the end of the Phase 1 clinical trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 5, 2015
January 22, 2015
April 9, 2014
Most Searched Private Companies
Sponsored Financial Commentaries